POS6 COST OF FALLS IN LONG-TERM CARE FACILITIES (LTCFS)  by Carroll, NV et al.
A163Abstracts
after primary treatment. METHODS: Data derive from the
ﬁnancial database of the National Health Insurance Fund
Administration (OEP) and based on the S7200 ICD code and
Diagnosis Related Groups 371A,B,C,H,K 374A,B,C and
375A,B,C. Patients with polytrauma or severe comorbidities
were excluded from the study. Our retrospective analysis
includes patients with femoral neck fracture identiﬁed with
Social Security Identiﬁcation number (TAJ) and discharged in
2000. We calculated the cost of acute and chronic hospital care,
outpatient care and sick-pay. The following exchange rate 
was used: 1 Euro (EUR) = 253,23 Hungarian Forint (HUF).
RESULTS: Altogether 518 patients were included into the study.
The average cost per patient (for both with and without com-
plications) was as follow. Acute inpatient care: arthroplasty 1357
EUR, screw ﬁxation 1033EUR, DHS: 925EUR. Chronic inpa-
tient care: arthroplasty 24EUR, screw ﬁxation 75EUR, DHS: 52
EUR. Sick-pay: arthroplasty 896EUR, screw ﬁxation 994EUR,
DHS: 914EUR. Outpatient care: arthroplasty 21EUR, screw ﬁx-
ation 51EUR, DHS: 39EUR. Total health insurance expendi-
tures were: arthroplasty 2299EUR, screw ﬁxation 2153EUR,
DHS: 1930EUR. Total health insurance expenditures per patient
with complications were: arthroplasty 3063EUR, screw ﬁxation
3971EUR, DHS: 2481EUR. Total health insurance expenditures
per patient without complications were: arthroplasty 2215EUR,
screw ﬁxation 1743EUR, DHS: 1813EUR. The rate of further
treatment was arthroplasty 8.3%, screw ﬁxation 18.4%, DHS:
14.7%. CONCLUSIONS: We found the highest cost in patients
with complications in screw ﬁxation, while patients without
complications in arthroplasty. In both cases (with and without
complications) dynamic hip screw had the lowest cost.
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OBJECTIVES: We determined the cost-effectiveness of monthly
ibandronate compared to weekly bisphosphonate (BP) treat-
ments for women in the US, age ≥50 years, with prevalent radi-
ologic vertebral deformity and hip BMD T-score ≤-2.5.
METHODS: A Markov model was developed to evaluate the
lifetime cost-effectiveness of monthly ibandronate and weekly
BPs. Vertebral, hip, and wrist fracture efﬁcacy were assigned a
bisphosphonate class effect as estimated by the literature. Per-
sistence with weekly BPs was evaluated at rates reported from
observational studies (36% at year 1, 24% for years 2 through
5). Fifty-percent relative improvement in persistence (54% at
year 1, 36% for years 2 through 5) among women receiving
ibandronate was assumed based on previous improvements in
persistence for weekly BPs. Both fracture risk and mortality were
allowed to increase as patients aged. Yearly drug costs were ref-
erenced to wholesale acquisition costs for each BP. Direct health
resource costs for fracture states were estimated from published
literature and discounted 3% per annum. All costs were reported
in 2004 US$. RESULTS: More fractures were avoided (vs. no
treatment) with monthly ibandronate (94.13 per 1000 women)
than with weekly BPs (57.57 per 1000 women), resulting in low
lifetime fracture care costs/woman ($6726 and $6918, respec-
tively). Five-year drug costs/patient were $1138 with weekly BPs
and $1576 under conditions of improved persistence with
monthly ibandronate. The incremental cost per quality-adjusted
life year gained (vs. no treatment) was lower with monthly iban-
dronate ($26,725) compared to weekly BPs ($31,601). Chang-
ing assumptions in the model to that of previously published
cost-effectiveness models produced similar results, providing
external validity for this model. CONCLUSION: Ibandronate is
a cost-effective intervention for the treatment of postmenopausal
osteoporosis. Incremental persistence with BP therapy thus
improves the beneﬁt realized in patient populations. These ben-
eﬁts include fewer fractures for patients without signiﬁcant
increases in costs to payers.
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OBJECTIVE: To estimate the cost of falls in LTCFs.
METHODS: The study employed a non-randomized, before and
after comparison with control group design. A multi-facility
long-term care company provided data from residents institu-
tionalized between January 1, 2002 and October 30, 2004. Data
included Minimum Data Set (MDS) observations, Resource Uti-
lization Group (RUG) classiﬁcations, and demographics. An
index date was assigned to each resident to identify pre-and post-
periods. The index date was deﬁned as the date of the ﬁrst fall
for fallers and as the date of the ﬁfth MDS measurement for non-
fallers. Direct medical cost estimates were based on MDS mea-
sures of hospital, emergency room, and physician utilization and
on average Medicare reimbursement rates. Costs related to
changes in resident functioning were estimated from RUG
payment rates. Total reimbursement per resident per day (PRPD)
was calculated as the sum of RUG and medical service reim-
bursements. Fall-related costs were estimated by comparing
between-group differences in pre- to post-index period changes
in reimbursement. Regression analysis was used to control for
between-group differences. The dependent variable was the
natural log of post-period total reimbursement. Independent
variables included group, pre-period reimbursement, post-period
length of stay, age, gender, race, and severity of illness as mea-
sured by a modiﬁed Charlson Comorbidity Index. RESULTS:
The sample included 1298 fallers and 1509 non-fallers. Fallers
had substantially more fractures and higher medical services uti-
lization in the post-period than non-fallers. Total reimbursement
for fallers decreased from $107 to $37 PRPD compared to a
decrease from $98 to $24 for non-fallers. Regression analysis
indicated that reimbursement in the post-period was 40% higher
for fallers than non-fallers after controlling for demographic and
disease differences and pre-period reimbursement. CONCLU-
SION: Falls in LTCFs result in substantial costs, primarily due
to higher hospitalization rates.
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OBJECTIVES: The aim of the study is to analyze on a 3 years
follow up the 50–100% impaired ability to work related to
medial fracture of femoral neck of patients in active age group
regarding the surgical methods, the progressivity level of the
primary treatment, rehabilitation care, age group and residence
of patients, and the possible complications. METHODS: Data
derive from the database of the National Health Insurance Fund
Administration and based on the ICD-10 code S7200 (femoral
